Edgewise Therapeutics Inc Total Liabilities
Edgewise Therapeutics Inc total liabilities. Based on the latest financial reports, Edgewise Therapeutics Inc (EWTX) has total liabilities worth $25.32 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check EWTX financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Edgewise Therapeutics Inc (2019–2025)
Total liabilities of Edgewise Therapeutics Inc from 2019 to 2025. This chart illustrates how Edgewise Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Edgewise Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Edgewise Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Monday.Com Ltd
NASDAQ:MNDY
|
USA | $1.00 Billion |
|
Shanghai Xinmei Real Estate Co Ltd Class A
SHG:600732
|
China | CN¥28.84 Billion |
|
EREGLI DEM CEL FABR DL1
F:EDVA
|
Germany | €270.32 Billion |
|
Doximity Inc
NYSE:DOCS
|
USA | $172.85 Million |
|
Liechtensteinische Landesbank Aktiengesellschaft
STU:LLS1
|
Germany | €26.48 Billion |
|
Banijay Group NV
AS:BNJ
|
Netherlands | €9.98 Billion |
|
ENAGAS A.A. ADR1/2/EO150
F:EG40
|
Germany | €4.46 Billion |
|
Orla Mining Ltd
TO:OLA
|
Canada | CA$1.35 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Edgewise Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Edgewise Therapeutics Inc total assets.
Liquidity & Leverage Metrics
Edgewise Therapeutics Inc Total Liabilities Ratios Explained
Edgewise Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 22.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Edgewise Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Edgewise Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Edgewise Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $30.35 Million | +9.95% |
| 2024-12-31 | $27.60 Million | +30.16% |
| 2023-12-31 | $21.20 Million | +4.02% |
| 2022-12-31 | $20.39 Million | +87.88% |
| 2021-12-31 | $10.85 Million | -93.41% |
| 2020-12-31 | $164.56 Million | +297.54% |
| 2019-12-31 | $41.39 Million | -- |
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company… Read more